- Home
- NUVL vs RHI Comparison
NUVL vs RHI Comparison
Compare NUVL & RHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- RHI
- Stock Information
- Founded
- NUVL 2017
- RHI 1948
- Country
- NUVL United States
- RHI United States
- Employees
- NUVL N/A
- RHI N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- RHI Professional Services
- Sector
- NUVL Health Care
- RHI Consumer Discretionary
- Exchange
- NUVL Nasdaq
- RHI Nasdaq
- Market Cap
- NUVL 5.6B
- RHI 6.1B
- IPO Year
- NUVL 2021
- RHI N/A
- Fundamental
- Price
- NUVL $70.46
- RHI $54.69
- Analyst Decision
- NUVL Strong Buy
- RHI Hold
- Analyst Count
- NUVL 10
- RHI 6
- Target Price
- NUVL $113.10
- RHI $69.00
- AVG Volume (30 Days)
- NUVL 594.2K
- RHI 1.6M
- Earning Date
- NUVL 05-08-2025
- RHI 04-24-2025
- Dividend Yield
- NUVL N/A
- RHI 4.31%
- EPS Growth
- NUVL N/A
- RHI N/A
- EPS
- NUVL N/A
- RHI 2.44
- Revenue
- NUVL N/A
- RHI $5,795,837,000.00
- Revenue This Year
- NUVL N/A
- RHI $2.59
- Revenue Next Year
- NUVL N/A
- RHI $8.26
- P/E Ratio
- NUVL N/A
- RHI $22.44
- Revenue Growth
- NUVL N/A
- RHI N/A
- 52 Week Low
- NUVL $61.80
- RHI $51.55
- 52 Week High
- NUVL $113.51
- RHI $78.41
- Technical
- Relative Strength Index (RSI)
- NUVL 39.36
- RHI 45.70
- Support Level
- NUVL $67.47
- RHI $53.27
- Resistance Level
- NUVL $77.93
- RHI $55.14
- Average True Range (ATR)
- NUVL 3.15
- RHI 1.24
- MACD
- NUVL -0.44
- RHI 0.45
- Stochastic Oscillator
- NUVL 26.88
- RHI 81.97
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About RHI Robert Half Inc.
Robert Half Inc was founded in 1948, Robert Half provides temporary, permanent, and outcome-based staffing for both in-person and remote positions in the finance and accounting, technology, legal, marketing, and administrative fields. Its subsidiary consulting arm, Protiviti, specializes in technology, risk, auditing, and compliance matters. The firm generates its sales inside the U.S. and is one of the specialized firms in the fragmented U.S. staffing industry. The firm generates annual revenue of around $7 billion.